Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK31679 in Primary Hypercholesterolemia with NAFLD (Phase II)
CTR20230753Phase 2Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HSK31679 in hypercholesterolemia, metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started Mar 2023; status: completed.
02
Drugs
HSK31679
03
Conditions
hypercholesterolemiametabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20230753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230753.